Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA   US9216591084

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/26/2015 02/27/2015 03/02/2015 03/03/2015 03/04/2015 Date
11.04(c) 10.76(c) 10.89(c) 10.89(c) 11.055 Last
633 698 506 966 401 607 1 005 940 559 818 Volume
+1.85% -2.54% +1.21% 0.00% +1.52% Change
More quotes
Company
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.Its product portfolio includes Fanapt and Tasimelteon.The Fanapt product is a compound for the treatment of schizophrenia, the... 
More about the company
Surperformance© ratings of Vanda Pharmaceuticals Inc.
Trading Rating : Investor Rating :
More Ratings
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Full-screen chart
Financials ($)
Sales 2015 104 M
EBIT 2015 -40,3 M
Net income 2015 -40,1 M
Debt 2015 -
Yield 2015 -
Sales 2016 153 M
EBIT 2016 -14,5 M
Net income 2016 -17,6 M
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 4,15x
Capi. / Sales 2016 2,83x
Capitalization 432 M
More Financials
Latest news on VANDA PHARMACEUTICALS INC.
02/25 VANDA PHARMACEUTICALS : Reports Fourth Quarter 2014 and Full Year 2014 Financial..
02/19 VANDA PHARMACEUTICALS : posts 4Q profit
02/19 VANDA PHARMACEUTICALS : Results of Operations and Financial Condition, Financial..
02/19 VANDA PHARMACEUTICALS : Reports Fourth Quarter 2014 and Full Year 2014 Financial..
02/02 VANDA PHARMACEUTICALS : to Announce Fourth Quarter 2014 Financial Results on Feb..
01/29 VANDA PHARMACEUTICALS : to Participate in the Canaccord Genuity Rare Disease, Bi..
01/23 VANDA PHARMACEUTICALS : Announces Listing of a New Fanapt® Patent in the FDA Ora..
01/16 VANDA PHARMACEUTICALS : Announces Listing of a New Fanapt® Patent in the FDA Ora..
More news
Sector news Bio Therapeutic Drugs
03/03 ALKERMES : rsquo; Corporate Presentation to be Webcast at the Barclays Global He..
03/03 ACTELION : New Drug Application for selexipag (Uptravi) is accepted by the US FD..
03/03 MEDIVATION : Tuesday 3/3 Insider Buying Report: MDVN, QSR
Plus d'actualités du secteur Bio Therapeutic Drugs


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF